New treatment options using 5-HT3 receptor antagonists in rheumatic diseases

Current Topics in Medicinal Chemistry

Volumn 6, Issue 18, 2006, Pages 2035-2042

  Müller, Wolfgang ^a   Fiebich, Bernd L ^b   Stratz, Thomas ^a,c  

^a Hochrhein Institut fur Rehabilitationsforschung   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Rheumaklinik Bad Säckingen ^*  (Germany)

Author keywords

Antiinflammatory; Dexamethasone; Fibromyalgia; Systemic scleroderma; Tropisetron

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DEXAMETHASONE; GRANISETRON; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; LOCAL ANESTHETIC AGENT; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PREDNISOLONE; PRILOCAINE; PROSTAGLANDIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON; TUMOR NECROSIS FACTOR;

ALCOHOLISM; ANALGESIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; ARTHRALGIA; ARTHROPATHY; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CYTOKINE RELEASE; DEPRESSION; DISEASE EXACERBATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG TREATMENT FAILURE; FIBROMYALGIA; HUMAN; IC 50; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATION; METABOLIC INHIBITION; MIGRAINE; MYOFASCIAL PAIN; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOARTHRITIS; PAIN ASSESSMENT; POSTOPERATIVE VOMITING; PROSTAGLANDIN RELEASE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; STEM CELL TRANSPLANTATION; SYSTEMIC SCLEROSIS; TENDON DISEASE; TRIGGER POINT; VISUAL ANALOG SCALE;

ANALGESICS; HUMANS; RECEPTORS, SEROTONIN, 5-HT3; RHEUMATIC DISEASES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 33749510660     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778522122     Document Type: Review

References (46)

1. Hoyer, D.; Clarke, D.E.; Fozard, J.R.; Hartig, P.R.; Martin, G.R.; Mylecharane, E.J. VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994, 46, 157-203.
2. 3 receptor. Scand J. Rheumatol. 2004. 33 (Suppl. 119),2-8.
3. Hesketh, P. J.; Gandara, D. R. Sereotonin antagonists: A new class of antiemetic agents. J. Natl. Cancer Inst. 1991, 83,613-620.
4. 3 receptor antagonists. Scand J. Rheumatol. 2004, 33 (Suppl. 119),12-18.
5. 3-Rezeptoren. Z. Rheumatol. 1994,53,225-338.
6. 3 receptor antagonist. Scand. J. Rheumatol. 2000, 29 (Suppl. 113), 49-54.
7. 3 receptor antagonist tropisetron. Results of a randomized, double-blind, palcebo-controlled multicenter trial in 418 patients. Int. J. Clin. Phrmacol. Res. 2001. 21,1-13.
8. Späth M.; Stratz, T.; Färber L.: Haus, U.; Pongratz, D. Treatment of fibromyagia with tropisetron - dose and efficacy correlations. Scand. J. Rheumatol. 2004, 33 (Suppl. 119), 63-66.
9. Stratz, T.; Varga, B.; Müller, W. The influence of depression on the effect of tropisetron in the therapy of fibromyalgia. Z. Rheumatol. 2003,62,42-45.
10. Salemi, S.; Rethage, J.; Wollina, U.; Michel, B. A.; Gay, R. E.; Gay, S.; Sprott, H. Detection on interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J. Rheumatol. 2003, 30, 146-149.
11. 3,-Rezeptor-Antagonisten Tropisteron. Z. Orthop. 2002,140,394-398.
12. 3 receptor antagonist tropisetron. Scand. J. Rheumatol. 2004,33 (Suppl. 119),44-48.
13. Emberg, M.; Lundeberg, T.; Kopp, S. Effects on muscle pain by intramuscular injection of granisetron in patients with fibromyalgia. Pain 2003, 101, 275-281.
14. Shah, J. P.; Phillips, T.; Danoff, J. V.; Gerber, L. H. A novel microanalytical technique for assaying soft tissue demonstrates significant quantitative biochemical differences in 3 clinically distinct groups: Normal, latent, and active. Arch. Phys. Med. Rehabil. 2003, 84, A4.
15. 3 receptor antagonists in various rheumatic diseases - a clue to the mechanism of action of these agents in fibromyalgia? Scand. J. Rheumatol. 2000, 29 (Suppl. 113),66-71.
16. 3 receptor antagonist tropisetron. A double-blind study compared with methylprednisolone. Scand. J. Rheumatol. 2004, 33 (Suppl. 119),51-54.
17. Voog, O.; Alstergren, P.; Leibur, E.; Kallikorm, R.; Kopp, S. Immediate effects of the serotonin antagonist granisetron on temporomandibular joint pain in patients with systemic inflammatory disorders. Life Sci. 2000, 68, 591-602.
18. Hrycaj, P. Serotonin type 3 receptor antagonist tropisetron in the treatment of chronic inflammatory rheumatic conditions - preliminary clinical experience. Scand. J. Rheumatol. 2004, 33 (Suppl. 119),55-58.
19. 3 receptor antagonist tropisetron. Scand. J. Rheumatol. 2004, 33 (Suppl. 119),59-62.
20. Richardson, B. P.; Engel, G.; Donatsch, P.; Stadler, P. A. Identification of Serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985, 316,126-131.
21. 3 receptor antagonists reduce inflammatory pain in rats. Eur. J. Pharmacol. 1989.170 83-86.
22. Sufka, K.J.; Schomburg, F. M.; Giordano, J. Receptor mediation of 5-HT-inducted inflammation and nociception in rats. Pharmacol. Biochem. Behav. 1992,41, 53-56.
23. 3 receptor antagonists on the writhing response in mice. Gen. Pharmacol. 1995, 26, 1301-1306.
24. Doak, G. J.; Sawynok, J. Formalin-inducted nociceptove behaviour and edema: involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes. Neuroscience 1997, 80, 939-949.
25. 3 Receptors modulate spinal nociceptive reflexes. Brain Res. 1990, 510, 12-16.
26. Giordano, J.; Daleo, C.; Sacks, S. M. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. Eur. J. Pharmacol. 1998, 354, 13-14.
27. 3 receptor antagonists. Drugs 1997, 55, 20-39.
28. 3 in nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies. Neurosci. Lett. 1996. 208,203-207.
29. 3 receptor-mediated antinociception: possible release of GABA. J. Neurosci. 1991, 11, 1881-1888.
30. Libert, F.; Bonnefont, J.; Bourinet, E.; Doucet, E.; Alloui, A.; Hamon, M.; Nargeot, J.; Eschalier, A. Acetaminophen: a central analgesic drug that involves a spinal tropisetron-sensitive, non-5-HT(3) receptor-mediated effect. Mol. Pharmacol. 2004. 66, 728-734.
31. 3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J. Neurosci. 2002, 22, 1010-1019.
32. Woolf, C. J.; Salter M. W. Neuronal plasticity: increasing the gain in pain. Science 2000, 288, 1765-1769.
33. Linhart, O.; Obreja, O.; Kress, M. The inflammatory mediators serotonin, prostaglandin E2 and bradykinin evoke calcium influx in rat sensory neurons. Neuroscience 2003, 118, 69-74.
34. Riering, K.; Rewerts, Zieglgansberger, W. Analgesic effects of 5-HT3 receptor antagonists. Scand. J. Rheumatol. 2004, 33 (Suppl. 119),19-23.
35. Ferrell, W. R.; Russell, N. J. Extravasation in the knee induced by antidromic stimulation of articular C fibre afferents of the anaesthetized cat. J. Physiol. 1986, 3 79, 407-416.
36. 3-receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. Neuroreport 1990, 1, 104-106.
37. Holzer, P. Peptidergic sensory neurons in the control of vascular functions: mechanisms and significance in the cutaneous and splanchnic vascular beds. Rev. Physiol. Biochem. Pharmacol. 1992, 121,49-146.
38. Levine, J. D.; Clark R.; Devor, M.; Helms, C.; Moskowitz, M. A.; Basbaum, A. I. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984, 226, 547-549.
39. Lotz, M.; Carson, D. A.; Vaughan, J. H. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987,235, 893-895.
40. Menkes, C. J.; Renoux, M.; Laoussadi, S.; Mauborgne, A.; Bruxelle, J.; Cesselin, F. Substance P levels in the synovium fluid from patients with rheumatoid arthritis and osteoarthritis. J. Rheumatol. 1993. 20, 714-717.
41. Amalich, F.; de Miguel, E.; Perez-Ayala, C. Neuropeptides and interleukin-6 in human joint inflammation; relationship between intraticular substance P and interleukin-6 concentration. Neurosci. Lett. 1994,170,251-254.
42. Inoue, A.; Hashimoto, T.; Hide, I.; Nishio, H.; Nakata, Y. 5-Hydroxytryptamine-facilitated release of-substance P from rat spinal cord slices is mediated by nitric oxide and cyclic GMP. J. Neurochem. 1997,68,128-133.
43. 3A receptors in cells of the immune system. Scand. J. Rheumatol. 2004, 33 (Suppl. 119), 9-11.
44. 3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scand. J. Rheumatol. 2004,33 (Suppl. 119),28-32.
45. Khan, N. A.; Poisson, J. P. 5-HT3-receptor-chamels coupled with Na+ influx in human T cells: role in T cell activation. J. Neuroimmunol. 1999, 99,53-60.
46. 3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochem. Pharmacol. 2005, 70, 369-380.